scholarly journals Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM)–Campath Allogeneic Stem Cell Transplantation for Aggressive Non-Hodgkin Lymphoma: An Analysis of Outcomes from the British Society of Blood and Marrow Transplantation

2015 ◽  
Vol 21 (3) ◽  
pp. 483-488 ◽  
Author(s):  
Edward Truelove ◽  
Christopher Fox ◽  
Stephen Robinson ◽  
Rachael Pearce ◽  
Julia Perry ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Marrow Transplantation ◽  
British Society ◽  
Blood And Marrow Transplantation ◽  
Non Hodgkin Lymphoma

scholarly journals HSCT FOR NON-HODGKIN LYMPHOMA

JBMTCT ◽  
2021 ◽  
Vol 4 (1) ◽  
pp. 109-119
Author(s):  
Sociedade Brasileira de TMO SBTMO ◽  
Renata Baldissera ◽  
Abrahão Elias Hallack Neto ◽  
Renato Castro ◽  
Guilherme Perrini ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Marrow Transplantation ◽  
Hematopoietic Stem ◽  
Blood And Marrow Transplantation ◽  
Brazilian Society ◽  
Non Hodgkin Lymphoma

THE BRAZILIAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION (SBTMO) PRESENTS THE BRAZILIAN GUIDELINES ON HEMATOPOIETIC STEM CELL TRANSPLANTATION

Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myelogenous Leukemia: To Transplant or Not to Transplant? A Systematic Review of International Guidelines.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 1419-1419 ◽  
Author(s):  
Kai Hübel ◽  
Olaf Weingart ◽  
Frauke Naumann ◽  
Julia Bohlius ◽  
Keith Wheatley ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Marrow Transplantation ◽  
Allogeneic Transplantation ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Blood And Marrow Transplantation ◽  
Related Donor

Abstract Abstract 1419 Poster Board I-442 For more than 20 years high dose chemotherapy followed by allogeneic stem cell transplantation (SCT) has been considered as a reasonable approach for the treatment of patients with AML. Moreover, during the last decade new scientific and technical developments results in major changes of clinical practice of transplantation. Enhanced donor availabilities and new strategies, e.g. dose-reduced conditioning, now make allogeneic stem cell transplantation available to patients who do not have a related donor or would not tolerate high-dose chemotherapy due to age or comorbidities. Usually, the decision to start the work-up process for allogeneic transplantation in AML patients is based on the availability of a donor, the assignment to the cytogenetic risk group, and the response to induction therapy, as well as patient factors. However, there would be greater confidence in defining who should, or should not, receive an allograft if the available recommendations given in guidelines are consistent and similar. In this analysis, a comprehensive systematic literature search for best available evidence from controlled clinical trials was performed in the bibliographic databases MEDLINE, EMBASE and Cochrane Central. In addition, the websites of major organizations in Europe and the US (European Group for Blood and Marrow Transplantation, EBMT; European Society for Medical Oncology, ESMO; British Committee for Standards in Hematology, BCSH; American Society for Blood and Marrow Transplantation, ASBMT; National Comprehensive Cancer Network, NCCN) were screened and the specific databases of the National Guideline Clearinghouse and the Guideline International Network Database were also searched to identify the latest recommendations and guidelines. The following points were selected for systematic comparison of the best available evidence: Factors for risk assessment and categorization of AML, donor categories for allogeneic SCT (sibling donors / matched unrelated donors), allogeneic transplantation in first CR, allogeneic transplantation in relapse/progressive disease or second CR, and allogeneic transplants with reduced intensity conditioning regimen. Several interesting findings emerge from this analysis: 1) For patients with relapse or refractory disease donor availability should be explored and discussed, though this is not based on reliable evidence from randomized studies; 2) Patients in CR1 with intermediate or high risk disease who have a matched related donor available should receive allogeneic stem cell transplantation (intermediate risk; ASBMT: reasonable, NCCN: option); 3) For patients who lack a family donor the recommendations are not consistent; 4) Allogeneic transplantation with reduced conditioning in AML patients is feasible, but the superiority over standard therapeutic regimens has not been proven yet. In summary, current guidelines differ in critical points in the recommendation for allogeneic stem cell transplantation. Furthermore, it is likely that only well-defined subgroups of AML patients will benefit from stem cell transplantation. Disclosures: No relevant conflicts of interest to declare.

scholarly journals HSCT FOR HODGKIN LYMPHOMA

JBMTCT ◽  
2021 ◽  
Vol 4 (1) ◽  
pp. 101-108
Author(s):  
Sociedade Brasileira de TMO SBTMO ◽  
Alessandra Paz ◽  
Rosane Bittencourt ◽  
Decio Lerner ◽  
Camila Manca ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Marrow Transplantation ◽  
Hematopoietic Stem ◽  
Blood And Marrow Transplantation ◽  
Brazilian Society

THE BRAZILIAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION (SBTMO) PRESENTS THE BRAZILIAN GUIDELINES ON HEMATOPOIETIC STEM CELL TRANSPLANTATION

Allogeneic Stem Cell Transplantation Is Able to Induce Long-Term Remissions in Angioimmunoblastic T-Cell Lymphoma: A Retrospective Study From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

2009 ◽  
Vol 27 (24) ◽  
pp. 3951-3958 ◽  
Author(s):  
Charalampia Kyriakou ◽  
Carmen Canals ◽  
Jürgen Finke ◽  
Guido Kobbe ◽  
Jean-Luc Harousseau ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Marrow Transplantation ◽  
Cell Lymphoma ◽  
Angioimmunoblastic T Cell Lymphoma ◽  
Blood And Marrow Transplantation ◽  
European Group

Purpose To analyze the long-term outcome in terms of nonrelapse mortality (NRM), relapse rate (RR), progression-free survival (PFS), and overall survival (OS) in patients with angioimmunoblastic T-cell lymphoma (AITL) treated with allogeneic stem-cell transplantation (alloSCT). Patients and Methods Forty-five patients with AITL who had undergone an alloSCT between January 1998 and December 2005 and were registered in the European Group for Blood and Marrow Transplantation database were analyzed. Median age was 48 years (range, 23 to 68 years), 34 patients had received ≥ two lines of chemotherapy before alloSCT, and 11 patients had experienced treatment failure with a prior autologous stem-cell transplantation. Twenty-five patients underwent a myeloablative alloSCT, and 20 underwent a reduced-intensity alloSCT. Donors were HLA-identical siblings in 26 patients. Twenty-seven patients were allografted in chemotherapy-sensitive disease, and 18 were allografted in refractory disease. Results The cumulative incidence of NRM was 18%, 22%, and 25% at 3, 6, and 12 months, respectively. Patients with poor performance status had a significantly higher NRM (P = .01). RR was estimated as 16% and 20% at 2 and 3 years, respectively, and was lower in patients developing chronic graft-versus-host disease (cGVHD). PFS and OS rates were 62% and 53% and 66% and 64% at 1 and 3 years, respectively, and were significantly better in chemotherapy-sensitive patients. Conclusion AlloSCT represents a valid therapeutic option for patients with AITL. Both the lower RR after transplantation as well as the decreased RR in patients developing cGVHD after the alloSCT suggests the existence of a clinically relevant graft-versus-lymphoma effect.

Sign in / Sign up

Export Citation Format

Share Document